Bonus Biogroup Ltd. · TASE:BONS
Bonus Biogroup — IPO Roadshow (March 2026)
43 slides from Bonus Biogroup's IPO roadshow presentation, Mar 12, 2026
Slide 1: Company Presentation March 2026 Roadshow
1 All information herein is proprietary to Bonus Biogroup Ltd. Company Presentation March 2026 Roadshow (TASE: BONS) Harnessing Nature to Heal Issuer Free Writing Prospectus dated March 6, 2026 Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Relating to Preliminary Prospectus da
Slide 2: Disclaimer
2 2 Disclaimer This presentation has been prepared by Bonus Biogroup Ltd. (“we” or the “Company”) and is made for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sales of any securities in any state or jurisdi
Slide 3: Our Mission
3 We are priming regenerative mesenchymal stem cells to develop novel tissue engineering and cell therapy solutions Our Mission
Slide 4: Management team
4 Dror Ben David, Ph.D. COO Dr. Ben - David has played a key role in developing and scaling the company’s cell therapy and tissue engineering products. Previously our VP of R&D (2021 – 2022), he holds a Ph.D. in Medical Sciences from the Technion — IIT. Tomer Bronshtein, Ph.D. VP Innovation & Corp.
Slide 5: Investment Highlights
5 Investment Highlights Bonus Biogroup (TASE: BONS) is a late - stage biotech company developing 'next - generation’, innovative, cost - effective solutions for various indications in regenerative medicine with prevalent and unmet clinical needs Proprietary mesenchymal stem cell (MSC) technology pro
Slide 6: Dual and Synergistic Approach to MSC-based Therapies
6 Dual and Synergistic Approach to MSC - based Therapies BonoFill A regenerative medicine advanced therapy product candidate of a live human bone graft for treating bone defects based on the patient’s own cells, grown outside their body. MesenCure An enhanced allogeneic cell therapy product candidat
Slide 7: Our Proprietary Cell Formulation
7 Our Proprietary Cell Formulation • Maintains fresh and viable cells with a shelf life intended to support centralized manufacturing and enable potential global distribution under 2 – 8 ° C without the need for cryopreservation • Ready - to - act upon application • Avoids damaging effect of cryopre
Slide 8: BonoFill Applications
8 8 BonoFill Applications Preclinical development and follow on applications Clinical stage maxillofacial bones (P3) limb bones (P 2 ) (P3) completed clinical phase 2; (P2) clinical phase 2 ongoing; (PC) in preclinical development spine (PC) osteoporosis (PC) joint reconstruction (PC
Slide 9: BonoFill: A Live Human Bone Graft
9 Liposuction Isolate o steoprogenitors Seeding on a 3D scaffold Various applications in bone regeneration Semi - automatic culturing Injectable graft formulation BonoFill is a live human bone graft composed of mesenchymal cells sampled from the patient's own adipose tissue The cells are seeded onto
Slide 10: Bone Autografting: A Century-old Gold Standard Despite Challenges
10 Harvesting bone from the patient's body and transplanting it to another site remains the gold standard for treating sizable or other non - healing bone defects, despite considerable limitations: Complication rate ~50% Persistent infection rate or non - union ~20% Need revision surgeries ~ 40 % Au
Slide 11: Designed for Scale-Up and Scale-Out
11 Designed for Scale - Up and Scale - Out BonoFill manufacturing leverages a single - use, disposable bioreactor system ready for automation and designed to mimic the physiological microenvironment of living bone — generating cost - effective, high - density viable bone grafts in just 2 - 3 weeks.
Slide 12: The BonoFill Value Proposition
12 The BonoFill Value Proposition Potentially more effective, accessible, and affordable than current standard of care Bone auto - grafting : Requires additional bone harvesting surgery — leading to low success rates; care that is both complex and costly vs. A live human bone graft potentially suita
Slide 13: The BonoFill Market Opportunity
13 Total Addressable Market (TAM) Highlights: United States Only (2030) Minimal Serviceable Available Market (SAM) projection based on the number of bone grafting procedures in non - dental applications involving autografting in the SOC ~ K procedures per year TAM opportunity in current study in
Slide 14: BonoFill Clinical Results
14 BonoFill Clinical Results
Slide 15: Study Design and Top Line Results
15 Study Design • Design: Open - label, single - arm • Enrolment and Demographics: Thirty transplantations (Phase 1 and 2 ) were performed on 13 male and 14 female patients aged between 32 and 71 • Efficacy Endpoint: A chieving a natural and complete jawbone six months after transplantation, enablin
Slide 16: Examples of Using BonoFill to Treat Facial Bone Deficiencies
16 Regeneration of bone in the upper jaw Regeneration of bone in the lower jaw 1 Examples of Using BonoFill to Treat Facial Bone Deficiencies • Before treatment, the bone height was 2.9 mm • Three months after transplantation, the bone reached a height of 15.6 mm • At the end of the six - month foll
Slide 17: Ongoing Phase 2 Trial in Limb Bone Defects
17 Ongoing Phase 2 Clinical Trial to Treat Critical Bone Defects in the Limbs Using BonoFill Study Design • Design: Open - label, single - arm • Enrolment and Demographics: Up to 40 transplantations will be performed on male and female patients aged between 18 and 80. • Efficacy Endpoint: A chieving
Slide 18: Examples of Using BonoFill to Treat Bone Defects in the Limbs
18 Regeneration of a large 40 cc bone defect following valgus knee repair Before treatment A year after BonoFill • Impaired walking • Constant pain • Limited weight bearing • Improved walking • Less pain • Normal functions • No adverse events Rehabilitation from complex fracture of the forearm bones
Slide 19: Examples of Treating Critical Bone Defects in the Limbs
19 Examples of Using BonoFill to Treat Critical Bone Defects in the Limbs The world ’ s first joint fusion with BonoFill Rehabilitation from a critical - sized bone defect in the tibia Before treatment A year after BonoFill • Significant constant pain • Limited weight bearing • > 5 cm long bone gap
Slide 20: BonoFill is Well-Positioned for Reimbursement Negotiations
20 $57K Cost of autologous bone grafting in limb bone defects using SOC , including: $ 22 K Products used during the procedure, operating room, personnel, and blood transfusion $ 24 K Inpatient bed charges, diagnostic examinations and non - surgical drug expenses $ 2 K Postoperative follow - up visi
Slide 21: Additional Sources BonoFill
21 Additional Sources BonoFill Ben - David, D. et al. (2019). Autologous cell - coated particles for the treatment of segmental bone defects — a new cell therapy approach. Journal of Orthopaedic Surgery and Research, 14(1), 198. [ LINK ] Tzur, E. et al. (2021). Safety and Efficacy Results of BonoFil
Slide 22: MesenCure Applications
22 22 MesenCure Applications MesenCure : A Next - Generation Cell Therapy for Inflammation and Tissue Damage (P3) completed clinical phase 2; (PC) in preclinical development; (FO) follow on indication/market Preclinical development and follow on applications Clinical stage Respiratory distre
Slide 23: The Unresolved Global Challenge of ARDS
23 The Unresolved Global Challenge of ARDS* Healthcare Burden • 27% - 45% mortality • 10% - 15% of ICU admissions • >75% of survivors suffer long - term disabilities • 591K patients in the United States suffered from ARDS in 2023 Cost Burden • $108K - $158K in direct hospitalization costs per ARDS p
Slide 24: Historical Challenges Related to Treating ARDS and to MSCs
24 ARDS Challenges • Heterogeneity in etiology and patient profiles • Systemic involvement and comorbidities • Variability in clinical outcomes MSC Challenges • Donor and source tissue variabilities • Loss of therapeutic potency due to overexpansion and cryopreservation • Lack of standardization in
Slide 25: MesenCure: Differentiated by a Proprietary Approach to MSC Therapy
25 MesenCure : Differentiated by a Proprietary Approach to MSC Therapy The MesenCure innovation rests on multiple technological breakthroughs to overcome the limitations of conventional MSC therapies and to enhance their tissue regenerative and immune - modulatory potency: Unique growth conditions b
Slide 26: MesenCure advanced allogeneic cell therapy
26 MesenCure is an advanced allogeneic cell therapy and investigational new drug designed to overcome cell therapy limitations in treating inflammation and tissue damage, utilizing primed, proprietary MSCs with a lead indication in respiratory distress, including all - cause ARDS A proprietary compo
Slide 27: MesenCure Reduces Infiltration of Immune Cells Into the Lungs
27 MesenCure Reduces the Infiltration of Immune Cells Into the Lungs, Healing Pneumonia within 24 Hours — Preclinical Study (murine model) Pneumonia MesenCure Healthy lungs Alveoli Alveoli walls *
Slide 28: The MesenCure Value Proposition
28 The MesenCure Value Proposition Designed as a curative solution for Acute Respiratory Distress Syndrome (ARDS) Standard of Care: Steroids, mechanical ventilation, and other supportive measures — are not curative vs. Targets both inflammation and tissue damage via multiple mechanisms Off - label &
Slide 29: The MesenCure Market Opportunity
29 Total Addressable Market (TAM) Highlights Combined follow - on global market for pneumonia, asthma, and COPD by 2031, where MesenCure can target additional indications TAM opportunity in all - cause ARDS in the United States alone by 2030 , based on potential direct savings to the healthcare syst
Slide 30: MesenCure Clinical Status
30 MesenCure Clinical Status Completed a Phase 2 trial in severely ill patients with respiratory distress due to COVID - 19 pneumonia, demonstrating a 68% reduction in mortality rate and a 57% decrease in invasive ventilation for patients treated with MesenCure vs. the SOC P2 IND application cleared
Slide 31: MesenCure Clinical Results
31 MesenCure Clinical Results
Slide 32: Completed Phase 2 Clinical Trial for Respiratory Distress
32 Completed Phase 2 Clinical Trial for the Treatment of Respiratory Distress with MesenCure Severely ill patients with respiratory distress due to COVID - 19 pneumonia diagnosed with SpO2 ≤93% in room atmosphere and presenting bilateral pulmonary infiltrates (inclusive of Phase 1). Design: Open - l
Slide 33: MesenCure Phase 2 Key Results
33 68 % Reduction in 30 - day all - cause mortality ( p < 0.05) 9.4 Reduction in length of hospital stay in those patients admitted for greater than seven days ( p < 0.01) 57 % Reduction in the need for invasive ventilation ( p < 0.05) Patients treated with MesenCure discharged from the hospital up
Slide 34: Rapidly Healed Pneumonia and Improved Respiratory Functions
34 One month after MesenCure treatment, breathing is normal, and pneumonia has dramatically reduced to a median of 0% coverage of the lung area ( p < 0.0001) Before MesenCure treatment, a median of 53 % of the patients ’ lung area was congested with inflammatory infiltrates (IQR: 25 % - 65 %), which
Slide 35: MesenCure is Well-Positioned for Reimbursement Negotiations
35 10 – 39 days in the ICU 8 – 23 days on ventilation 17 – 47 days in the hospital $41K – $60K (38% savings from adopting MesenCure) $67K – $90K (residual cost with MesenCure in the U.S.) 68 % less mortality 57% less invasive ventilation 38 % less hospital stay* $ 43 K – $ 62 K per patient per year
Slide 36: Additional Sources MesenCure
36 Additional Sources MesenCure Bronshtein, T. et al. MesenCure — an enhanced cell therapy explicitly developed for treating acute respiratory distress in covid - 19 : from benchtop to bedside. Cytotherapy 23 , S 21 - 22 ( 2021 ). [ LINK ] Bronshtein, T. et al. Possible Divergent Local and Periphera
Slide 37: Advanced GMP Facility for R&D and Manufacturing
37 37 Advanced GMP Facility for R&D and Manufacturing of Tissue Engineering and Cell Therapy Products • GMP compliant according to FDA and EMA • Two production halls for BonoFill and MesenCure • Production capacity suitable for commercial activity • Advanced R&D center for cell therapy and tissue en
Slide 38: Intellectual Property
38 Intellectual Property In the US, Europe, and Asia 71 approved patents 10 pending applications 6 patent families 38
Slide 39: Strategic Partnership for U.S. Commercialization
39 Strategic Partnership for U.S. Commercialization We are evaluating a potential commercialization partner with a proven track record in supporting advanced therapies through comprehensive commercialization solutions and strong distribution capabilities across the U.S.
Slide 40: Partnership Goal and Objectives
40 Leverage a partner ’ s expertise to maximize the commercial success of BonoFill and MesenCure following marketing approval, with potential support in the following areas: Developing Commercialization Infrastructure Partnership Goal and Objectives U.S. Implementation Efforts Strategic planning for
Slide 41: Catalysts: 2026
41 Upcoming Event Phase 3 Phase 2 Phase 1 Preclinical Product Candidate Phase 3 trial planned for 2026 in the U.S. BonoFill for maxillofacial bone defects in jaw bones BonoFill for defects in limb bones incapable of healing or untreatable BonoFill for bone augmentation in osteoporosis or low bone de
Slide 42: Investment Highlights
42 Investment Highlights Bonus Biogroup (TASE: BONS) is a late - stage biotech company developing 'next - generation’, innovative, cost - effective solutions for various indications in regenerative medicine with prevalent and unmet clinical needs Proprietary mesenchymal stem cell (MSC) technology pr
Slide 43: Thank you
43 All information herein is proprietary to Bonus Biogroup Ltd. Thank you The 2024 Advanced Therapies Award in Cell Therapy Biotech Innovation